BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28829799)

  • 1. Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways.
    Chen YJ; Wang WH; Wu WY; Hsu CC; Wei LR; Wang SF; Hsu YW; Liaw CC; Tsai WC
    PLoS One; 2017; 12(8):e0183368. PubMed ID: 28829799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.
    Henderson SE; Ding LY; Mo X; Bekaii-Saab T; Kulp SK; Chen CS; Huang PH
    Neoplasia; 2016 Dec; 18(12):765-774. PubMed ID: 27889645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition.
    Zhang M; Pan Y; Dorfman RG; Chen Z; Liu F; Zhou Q; Huang S; Zhang J; Yang D; Liu J
    Oncotarget; 2016 Apr; 7(16):22285-94. PubMed ID: 26993777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.
    Sato N; Ohta T; Kitagawa H; Kayahara M; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
    Int J Oncol; 2004 Mar; 24(3):679-85. PubMed ID: 14767553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
    Duo J; Ma Y; Wang G; Han X; Zhang C
    DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition.
    Wei D; Lu T; Ma D; Yu K; Zhang T; Xiong J; Wang W; Zhang Z; Fang Q; Wang J
    Life Sci; 2018 Oct; 211():224-237. PubMed ID: 30248347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone acetyltransferase inhibitor II induces apoptosis in glioma cell lines via the p53 signaling pathway.
    Xu LX; Li ZH; Tao YF; Li RH; Fang F; Zhao H; Li G; Li YH; Wang J; Feng X; Pan J
    J Exp Clin Cancer Res; 2014 Dec; 33(1):108. PubMed ID: 25523932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells.
    Tomoyasu C; Kikuchi K; Kaneda D; Yagyu S; Miyachi M; Tsuchiya K; Iehara T; Sakai T; Hosoi H
    Oncol Rep; 2019 Jan; 41(1):643-649. PubMed ID: 30365145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595.
    Minjie S; Defei H; Zhimin H; Weiding W; Yuhua Z
    Tumour Biol; 2015 Nov; 36(11):9015-22. PubMed ID: 26084607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
    Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
    Zhu Y; Yuan T; Zhang Y; Shi J; Bai L; Duan X; Tong R; Zhong L
    Drug Des Devel Ther; 2019; 13():4321-4330. PubMed ID: 31908417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel HDAC inhibitor AR-42-induced anti-colon cancer cell activity is associated with ceramide production.
    Xu W; Xu B; Yao Y; Yu X; Shen J
    Biochem Biophys Res Commun; 2015 Aug; 463(4):545-50. PubMed ID: 26026677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
    Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
    J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling.
    Chen L; Feng D; Qian Y; Cheng X; Song H; Qian Y; Zhang X; Wu Y; Lv H; Liu Q; Cheng G; Yang B; Gu M
    Phytomedicine; 2021 May; 85():153537. PubMed ID: 33744595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
    Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
    Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
    Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
    PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.